c-MYC contributes to initiate and maintain tumorigenesis in many human cancers and regulates the antitumor immune response through CD47 and PD-L1 (Casey et al., 2016), providing new insights into immunotherapies and epigenetic therapies (Casey et al., 2016; Dang, 2012; Stine et al., 2015; Topper et al., 2020). The gene discussed is CD47; the disease is cancer.